Loading stock data…
ELDN
$3.69+0.05 (+1.37%)
After Hours$3.75+0.06 (+1.63%)· Last close May 1
Eledon Pharmaceuticals, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Eledon Pharmaceuticals, Inc. in the Healthcare sector is trading at $3.69. The stock is currently 20% below its 52-week high of $4.60, remaining 41.4% above its 200-day moving average. Technical signals show neutral RSI of 61 and bearish MACD signal, explaining why ELDN maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 61) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.69
Potential Upside
5%
Whystock Fair Value$3.87
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amy...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$317.72M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.84
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-56.26%
Volume
Today's trading volume
1.22M
Recent News
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug
NewcelX Ltd. reported its 2025 financial results, with leadership emphasizing a "transformative year" marked by merger completion, balance sheet improvements, and progress in its lead Type 1 diabetes program, NCEL-101. Ronen Twito, executive chairman and CEO, said the company is positioning NCEL-101, developed in partnership with Eledon Pharmaceuticals Inc., as its primary long-term value driver. Twito added that the company's stem cell-derived islet platform, combined with targeted immune prote
Here is Why Eledon Pharmaceuticals (ELDN) is an Unstoppable Stock That Could Double Your Money
Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) is one of the 10 Unstoppable Stocks That Could Double Your Money. Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) is one of the unstoppable stocks that could double your money. On March 19, Eledon reported its financial results for the full year 2025, highlighting the clinical advancement of its anti-CD40L antibody, tegoprubart. The company […]
Eledon Pharmaceuticals Touts Tegoprubart Safety in BESTOW Kidney Transplant Data at Leerink Conference
Eledon Pharmaceuticals (NASDAQ:ELDN) used a presentation at the Leerink Partners Global Healthcare Conference to highlight what CEO David-Alexandre Gros described as a rapid expansion in clinical experience with its lead CD40 ligand antibody, tegoprubart, across multiple transplant settings. Gros sa
NewcelX and Eledon partner for NCEL-101 programme
The partnership draws on clinical experience from over 100 transplant patients treated with tegoprubart.
Eledon Pharmaceuticals Highlights BESTOW Data, Phase III Plans and FDA Timeline for “Tego” at Conference
Eledon Pharmaceuticals (NASDAQ:ELDN) executives discussed recent clinical results and upcoming regulatory plans for its investigational immunosuppressive therapy, referred to in the discussion as “tego,” highlighting data from the company’s Phase II BESTOW kidney transplant study, longer-term follow